Investors
Information Disclosure
-
RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER AND APPOINTMENT OF CHIEF EXECUTIVE OFFICER2022.07.27
-
CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE2022.07.15
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 20222022.06.30
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKETING OF CATEGORY 1 INNOVATIVE DRUG “TQ-B3101 CAPSULE”2022.06.27
-
VOLUNTARY ANNOUNCEMENT - ACQUISITION OF F-STAR THERAPEUTICS, INC.2022.06.23
-
ADJUSTMENT TO CONVERSION PRICE OF EURO750,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 20252022.06.17
-
VOLUNTARY ANNOUNCEMENT CATEGORY 1 INNOVATIVE DRUG “TQC2938” INJECTION APPROVED FOR CLINICAL TRIAL2022.06.14
-
NEXT DAY DISCLOSURE RETURN2022.06.08